J Cancer 2022; 13(6):1785-1795. doi:10.7150/jca.68453 This issue

Research Paper

Global Research Trends on the Treatment of Diffuse Large B-Cell Lymphoma: A Bibliometric and Visualized Study

Qintong Duan1, Yufeng Li1, Lijia Ou1, Yajun Li2, Ruolan Zeng2, Yizi He2, Tao Pan2, Siwei Chen1, Huan Chen3, Hui Zang4, Hui Zhou2✉, Ling Xiao1✉

1. Department of Histology and Embryology of School of Basic Medical Sciences, Central South University, Changsha, Hunan, China.
2. Department of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, Hunan, China.
3. Department of Pathology and Pathophysiology of School of Basic Medical Sciences, Hunan University of Medicine, HuaiHua 418000.
4. Department of Human Anatomy and Histoembryology of School of Basic Medical Sciences, Yiyang Medical College, Yiyang.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Duan Q, Li Y, Ou L, Li Y, Zeng R, He Y, Pan T, Chen S, Chen H, Zang H, Zhou H, Xiao L. Global Research Trends on the Treatment of Diffuse Large B-Cell Lymphoma: A Bibliometric and Visualized Study. J Cancer 2022; 13(6):1785-1795. doi:10.7150/jca.68453. Available from https://www.jcancer.org/v13p1785.htm

File import instruction

Abstract

Graphic abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. Treatment of DLBCL has improved greatly in recent decades, with thousands of papers published. We conducted a bibliometric analysis of the literature on DLBCL treatment, and discussed cooperation among authors, countries, and institutions, and identified research hotspots for DLBCL treatment. We searched the Web of Science Core Collection (WOSCC) using “Diffuse Large B Cell Lymphoma or DLBCL” and “Treatment or Therapy or Clinical Trial” as the subject terms, and analyzed the publication year, research direction, country/region, institution, author, source publication, distribution of funding institutions, and other conditions provided by the database. In addition, scientometrics software was used to analyze literature citations and cooperative publications. Bibliometric analyses were performed using https://bibliometric.com/app and VOSviewer. Network maps were generated to evaluate collaborations between different authors, countries, institutions, and keywords. A total of 7,255 studies on treatment of DLBCL were retrieved from the WOSCC on February 19, 2021. We found that the number of publications increased gradually from 1999 to 2021, and this trend was relatively stable in the past 3 years. The countries that produced the most publications were the United States, China, and Japan. Among institutions, University of Texas MD Anderson Cancer Center published the most manuscripts. Furthermore, the United States also had the most annual publications, citations, distribution of journal sources, and funding. Cooperative research between countries is also relatively important to treatment of DLBCL. Therapeutic regimens such as CHOP and R-CHOP, and immunotherapy (CAR-T, PD1/PDL1, and CAR-NK, etc.), have received increased attention. Bibliometric analysis of studies related to DLBCL treatment can help researchers and clinical workers quickly understand the hotspots and development trends in this field, and provide reference for the formulation of public health policies.

Keywords: diffuse large B-cell Lymphoma (DLBCL), treatment, research progress, bibliometric analysis, Visualized, VOSviewer